Merck partners with Habitat for Humanity in asthma awareness effort

Share this article:
Merck partners with Habitat for Humanity in asthma awareness effort
Merck partners with Habitat for Humanity in asthma awareness effort
Merck is launching Build Smart, Breathe Easier, an asthma awareness campaign starring celebrity carpenter Carter Oosterhouse, who will build four homes with asthma-healthy features.

Oosterhouse, a fixture on HGTV, will build houses with low-income families that suffer from asthma in Atlanta, Detroit, LA and Philadelphia as part of the campaign, for which Merck is partnering with Habitat for Humanity and the Asthma and Allergy Foundation of America (AAFA). The campaign will emphasize the use of easy-to-clean, irritant-free materials, such as non-toxic paint and hard-surface floors, as a means of limiting asthma flare-ups, and will raise awareness of household asthma triggers such as dust mites, mold, pet dander and strong fumes and ways to control them.

Merck and AAFA employees will volunteer their labor on the homes, working alongside Oosterhouse and four families selected by Habitat for Humanity on homes built according to the principles of AAFA's Asthma and Allergy Friendly Certification Program.  

"Our goal is to educate about how to take steps to try to reduce triggers in the home," said Oosterhouse on the campaign's Facebook page, "and to encourage people with asthma to speak with their doctor about the appropriate treatment approach for their individual needs."

The campaign's Facebook page, though bereft of branding, does link to Merck-branded “asthma tracking tool (MerckEngage),” “self-management action plan” and “therapy assessment questionnaire.”

Merck's respiratory portfolio includes Asmanex, Dulera, Foradil, Proventil and Singulair for asthma as well as Clarinex and Nasonex for allergies.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...